Who is sponsoring NCT02889653?

NCT02889653 is sponsored by National Cerebral and Cardiovascular Center, Japan.

What drugs are being tested in NCT02889653?

Interventions in NCT02889653: Any oral antithrombotics (antiplatelets or anticoagulants).

What condition does NCT02889653 study?

NCT02889653 studies Cerebrovascular and Cardiovascular Diseases.

Is NCT02889653 still recruiting?

NCT02889653 is currently completed. Last updated 7 November 2023.

Last reviewed 2023-11-07 · How we verify

NCT02889653: BAT2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Bleeding With Antithrombotic Therapy Study 2

Completed Last updated 7 November 2023

What this trial tests

trial testing Any oral antithrombotics (antiplatelets or anticoagulants) in Cerebrovascular and Cardiovascular Diseases in 5,306 participants. Completed in 1 March 2021.

Timeline

1 October 2016

Primary endpoint
1 March 2020

1 March 2021

Quick facts

Lead sponsor	National Cerebral and Cardiovascular Center, Japan
Status	Completed
Study type	OBSERVATIONAL
Enrollment	5,306
Start date	1 October 2016
Primary completion	1 March 2020
Estimated completion	1 March 2021
Sites	9 locations across Japan

Drugs / interventions tested

Any oral antithrombotics (antiplatelets or anticoagulants) — full drug profile →

Conditions studied

Cerebrovascular and Cardiovascular Diseases — all drugs for Cerebrovascular and Cardiovascular Diseases →

Sponsor

National Cerebral and Cardiovascular Center, Japan — full company profile →

Who can join

Eligibility, any sex, with Cerebrovascular and Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

ISTH major bleeding
Time frame: within 2 years

Sponsor's own description

The purpose of this study is to determine the incidence and severity of bleeding complications in patients with cerebrovascular and cardiovascular diseases treated with oral antithrombotic therapy.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Increased Cerebral Small Vessel Disease Burden With Renal Dysfunction and Albuminuria in Patients Taking Antithrombotic Agents: The Bleeding With Antithrombotic Therapy 2.
Tanaka K, Miwa K, Takagi M, Sasaki M, et al · · 2022 · cited 10× · PMID 35253443 · DOI 10.1161/jaha.121.024749
The bleeding with antithrombotic therapy study 2: Rationale, design, and baseline characteristics of the participants.
Takagi M, Tanaka K, Miwa K, Sasaki M, et al · · 2020 · cited 4× · PMID 33598561 · DOI 10.1177/2396987320960618
Impact of Basal Ganglia Perivascular Spaces on Ischemic and Hemorrhagic Risks in Patients Taking Antithrombotic Therapies.
Iwamoto S, Miwa K, Koga M, Yoshimura S, et al · · 2026 · PMID 41861278 · DOI 10.1212/wnl.0000000000214745
Prediction Model to Optimize Long-Term Antithrombotic Therapy Using Covert Vascular Brain Injury and Clinical Features.
Miwa K, Tanaka K, Koga M, Tanaka K, et al · · 2025 · PMID 40534562 · DOI 10.1161/strokeaha.125.050859
Poster Abstracts
· 2017

Verify or expand the search:

Other National Cerebral and Cardiovascular Center, Japan trials

Trials by the same sponsor.

NCT06072118 — Adrenomedullin for CADASIL · Phase 2 · completed
NCT04559191 — Atheroma Progression and Vulnerability Under Continuous Glucose Monitoring · Phase 4 · unknown
NCT04864171 — REASSURE-NIRS Registry · recruiting
NCT04345627 — Japanese Lead Extraction Registry · recruiting
NCT03729232 — Japanese Catheter Ablation Registry · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02889653 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cerebral and Cardiovascular Center, Japan
Last refreshed: 7 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02889653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing